Retraction of high-profile paper on cancer drug timing could hand ammo to China hawks - Endpoints News
Nature Medicine has retracted a high-profile study on cancer drug timing that originated from a China-based clinical trial. The retraction is expected to fuel political tensions regarding the reliability of Chinese biotech research and the Biosecure Act.
Why it matters
The intersection of scientific integrity and geopolitical competition highlights the growing scrutiny of international research collaborations in the biopharma sector.
Topic Hubs AI drug discovery: News, analysis and interviews Antibody-drug conjugates: The next wave of targeted cancer drugs Biopharma M&A and dealmaking: Who’s buying and why Biopharma people moves: CEO changes, executive hires, board positions Biotech IPOs: Tracking the market for new public offerings Biotech venture funding: Who’s raising and where the money is going Cell and gene therapy manufacturing: Scaling the next frontier China biotech: Licensing deals and the Biosecure Act CRISPR and gene editing: The push for in vivo therapies Drug pricing and the IRA: Tracking the government's negotiation power FDA policy and drug approvals: What’s changing for biopharma GLP-1 drugs: The obesity pipeline race and what's next Channels All News In Focus Special AI Bioregnum Biotech Voices Cell/Gene Tx China Coronavirus Deals Diagnostics Discovery FDA+ Financing Health Tech Law Letters to the Editor Manufacturing Marketing Nikkei Biotechnology Opinion Outsourcing Peer Review People Pharma R&D Startups Weekly Webinars Signal More Work at Endpoints Biopharma Jobs Letter to Editors Editorial Standards IPO Tracker Webinars Events Sponsored Posts Advertise Privacy Policy Endpoints Merch About Us Help SIGN UP LOG IN {@!--LOGTO_LOGIN_BUTTON--!@} June 25, 2026 11:11 AM EDT R&D Re trac tion of high-pro file pa per on can cer drug tim ing could hand am mo to Chi na hawks Elizabeth Cairns Senior biopharma journalist Na ture Med i cine has re tract ed a high-pro file pa per it pub lished in Feb ru ary de tail ing the re sults of a Chi na-based tri al sug gest ing that can cer …
The article reports on the retraction and its political consequences, acknowledging the 'China hawk' perspective without adopting it.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in